share_log

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/11/05 05:04

Moomoo AI 已提取核心信息

SciSparc reported revenue of $840,000 for H1 2024, down from $1.97M in H1 2023, primarily from its Wellution brand nutraceutical business. Operating loss increased 19% to $3.53M, driven by higher R&D expenses of $841,000 and G&A costs of $2.63M. The company ended the period with $2.62M in cash.The company has undertaken several strategic initiatives, including signing an LOI to spin off its pharmaceutical portfolio, entering a patent license agreement for SCI-160, and advancing a merger with AutoMax Motors. SciSparc extended a $4.25M bridge loan to AutoMax and secured a $20M standby equity purchase agreement with YA II PN.Looking ahead, SciSparc plans to sell its 52.73% stake in MitoCareX Bio to a U.S. public company for up to $7M based on milestones. Management indicates additional capital will be required to fund operations and complete product development, with no significant pharmaceutical revenue expected in the near term.
SciSparc reported revenue of $840,000 for H1 2024, down from $1.97M in H1 2023, primarily from its Wellution brand nutraceutical business. Operating loss increased 19% to $3.53M, driven by higher R&D expenses of $841,000 and G&A costs of $2.63M. The company ended the period with $2.62M in cash.The company has undertaken several strategic initiatives, including signing an LOI to spin off its pharmaceutical portfolio, entering a patent license agreement for SCI-160, and advancing a merger with AutoMax Motors. SciSparc extended a $4.25M bridge loan to AutoMax and secured a $20M standby equity purchase agreement with YA II PN.Looking ahead, SciSparc plans to sell its 52.73% stake in MitoCareX Bio to a U.S. public company for up to $7M based on milestones. Management indicates additional capital will be required to fund operations and complete product development, with no significant pharmaceutical revenue expected in the near term.
SciSparc报告2024年上半年的营业收入为840,000美元,低于2023年上半年的197万,主要来自其Wellution品牌的营养保健业务。经营亏损增加了19%,达到了353万,主要是由于研发费用为841,000美元和管理费用为263万。该公司在此期间结束时现金为262万。该公司已采取几项战略措施,包括签署意向书以剥离其药品组合,进入SCI-160的专利许可协议,并推进与AutoMax Motors的合并。SciSparc向AutoMax提供了425万的桥接贷款,并与YA II PN签署了2000万的备用股权购买协议。展望未来,SciSparc计划以最高700万的价格将其在MitoCareX Bio中的52.73%股份卖给一家美国上市公司,这个价格是基于里程碑的。管理层表示,未来需要额外的资本来支持运营和完成产品开发,近期内预计不会有显著的药品营业收入。
SciSparc报告2024年上半年的营业收入为840,000美元,低于2023年上半年的197万,主要来自其Wellution品牌的营养保健业务。经营亏损增加了19%,达到了353万,主要是由于研发费用为841,000美元和管理费用为263万。该公司在此期间结束时现金为262万。该公司已采取几项战略措施,包括签署意向书以剥离其药品组合,进入SCI-160的专利许可协议,并推进与AutoMax Motors的合并。SciSparc向AutoMax提供了425万的桥接贷款,并与YA II PN签署了2000万的备用股权购买协议。展望未来,SciSparc计划以最高700万的价格将其在MitoCareX Bio中的52.73%股份卖给一家美国上市公司,这个价格是基于里程碑的。管理层表示,未来需要额外的资本来支持运营和完成产品开发,近期内预计不会有显著的药品营业收入。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息